According to a report in Globes, Edwards Lifesciences (NYSE: EW) agreed to acquire the remaining stake in Vectorious Medical Technologies.
The report states that Edwards’ deal values Vectorious at $497 million. It executed the acquisition in two stages, the report said, acquiring 52% of the company at a similar valuation in 2023. Today, the report says Edwards has acquired the remaining 48% stake to absorb the company fully.
Edwards Lifesciences has confirmed the acquisition with MassDevice.
Vectorious Medical Technologies develops a miniature heart pressure sensor implant called V-LAP. It designed its V-LAP to enable the remote monitoring of the heart and congestion status. It also allows for the self-adjustment of diuretics.
V-LAP, implanted in the heart’s interatrial septum through a minimally invasive procedure, measures left atrial pressure. It transmits data that enables physician-directed patient self-management of chronic heart failure.
Patients can also utilize a dedicated mobile application with daily data translated from the left atrium. Vectorious aims for the device to prevent disease deterioration and repeated hospitalizations.
Last year, Vectorious Medical announced the first implant of the V-LAP sensor in a U.S. patient.
Edwards is a leader in replacement heart valve technology, with its Sapien and Evoque platforms representing two of its largest portfolio pieces. The company has also been active on the M&A front, acquiring mitral valve company Innovalve for $300 million last year. A week before that deal, it entered into a series of deals with Affluent Medical, agreeing to pay $16.3 million for licensing and development efforts involving Affluent’s Kalios adjustable mitral annulus and mitral valve technology.
The company also has another large deal in the balance right now, as its attempt to acquire valve maker JenaValve currently faces legal scrutiny.
Statement from Edwards on the deal
An Edwards spokesperson issued the following statement to MassDevice via email, confirming the acquisition:
“We are pleased to announce that Edwards Lifesciences has fully acquired Vectorious Medical Technologies, a company Edwards has followed closely since their initial investment in 2020.
“Based in Tel Aviv, Vectorious will operate as a wholly owned subsidiary of Edwards. Vectorious’ V-LAP technology, a breakthrough treatment for heart failure, joins other Edwards technologies in pioneering new solutions for complex patient needs.”
